This week's roundup of Houston innovators includes Kathryn Worsham Humphries of All You Need Method, Heath Butler of Mercury Fund, and Serafina Lalany of HX. Courtesy photos

Editor's note: In the week's roundup of Houston innovators to know, I'm introducing you to three innovators who have tons to share — from recent venture capital data and observations to public relations and marketing tips for startups.

Kathryn Worsham Humphries, co-founder of All You Need Method

What does your company plan on bringing into the new year — and how do you plan to communicate your efforts? Photo courtesy of All You Need Method

It's a new year — and it's time for a new marketing and public relations plan for your startup. Thankfully, that's exactly what Houstonian Kathryn Worsham Humphries and her Los Angeles-based business partner Carla M. Nikitaidis specialize in with their new company, All You Need Method. The duo penned a guest column for InnovationMap last week with tips for refocusing on your target audience and prioritizing authenticity.

"Remember, these challenging times will pass," they write. "There is massive opportunity for the businesses and brands who are willing to reflect, pivot, and plan for a brighter future." Read more.

Heath Butler, network partner at Mercury Fund

Mercury Fund's Heath Butler joins the Houston Innovators Podcast this week to discuss Houston, venture capital, and more. Photo via mercuryfund.com

After 14 years at human resources company Insperity, Heath Butler has a specialty when it comes to thinking about the future of work. Butler was recently promoted within Mercury and the the move represents another aspect the firm is focusing on — something Butler discusses on last week's Houston Innovators Podcast episode.

"The world continues to be shaped by how the workforce and the workplace — and the actual work gets — done, and that couldn't have been put to the forefront more than during COVID," Butler says. "The promotion really reflects my focus on building out a very broad and deep theme for the firm around the future of work." Read more and stream the episode.

Serafina Lalany, chief of staff at Houston Exponential

HX has released a report on Houston venture capital. Photo courtesy of Serafina Lalany

Serafina Lalany and her team at Houston Exponential have crunched the numbers again to look at what sort of venture capital deals Houston startups brought in last year.

According to her report based on Pitch Book data, the Bayou City dredged up $715 million across 117 VC deals in 2020 — a year marked by challenges and opportunities from the pandemic and the oil price drop.

In the report, Lalany found that 2020 VC trends in Houston included fewer, larger deals and a rise in angel investment. Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”